JPRN-UMIN000006981已完成2 期
Randomized phase II trial of daily administrations versus alternate-day administrations of S-1 in patients with advanced non-small cell lung cancer - NJLCG1102
orth Japan Lung Cancer Study Group0 个研究点目标入组 60 人开始时间: 2011年12月28日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)With interstitial pneumonitis or pulmonary fibrosis detectable on chest X-ray 2)Contraindication with S-1 3)With double cancer, multiple cancer 4)With malignant pleural, peritoneal effusion requiring drainage or pericardial effusion 5)With concurrent disease 6)With symptomatic brain metastasis 7)With severe diarrhea 8)Previous treatment with fluoropyrimidines such as S-1, UFT, 5-FU 9) Current use of flucytosine 10)Lactating, pregnant or possibly pregnant women, or those willing to become pregnant 11)Physician concludes that the patient's participation in this trial is inappropriate
研究者
相似试验
已完成
2 期
Randomized phase II study of daily administrations versus alternate-day administrations of TS-1 in advanced or recurrent gastric cancer.Advanced or recurrent gastric cancerJPRN-UMIN000004578Japanese Foundation for Multidisciplinary Treatment of Cancer120
已完成
2 期
A randomized phase II study of daily administrations versus alternate-day administrations of S-1 with completely resected pathological stage I (T>2cm) of non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000011994Setouchi Lung Cancer Group93
进行中（未招募）
不适用
Phase II Clinical Trial ok weekly administration of oxaliplatin plus capecitabine and radioteraphy followed by surgery in patients with resectable locally advanced rectal cancerPre-surgical Locally advanced rectal cancer treatment.EUCTR2004-004475-12-ESGrupo de Tratamiento de los Tumores Digestivos
已完成
2 期
Continuous administration trial of phase II study of BSC-1 in patients with ATAdult T-cell leukemia/lymphomaJPRN-jRCT2080224825Minophagen Pharmaceutical Co., Ltd.10
已完成
不适用
Randomized Phase II trial on conventional administration (continuous administration for 2 weeks followed by one week interval) and alternate-day administration of adjuvant chemotherapy drug TS-1 in patients who underwent complete resection of non-small cell lung cancer.lung cancerJPRN-UMIN000011210Teikyo University school of Medicine80